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AIMS
Electronic healthcare records (EHRs) are increasingly used to store clinical information. A
secondary benefit of EHRs is their use, in an anonymized form, for observational research.
The Clinical Practice Research Datalink (CPRD) contains EHRs from primary care in the UK
and, despite 1083 peer-reviewed research publications, has never been used to obtain
pharmacogenetic samples. Using a statin-induced myopathy paradigm, we evaluated using
the CPRD to obtain patient samples for a pharmacogenetic study targeting 250 cases and
500 controls from UK general practitioner (GP) practices.
METHODS
The CPRD identified potential patients fitting specific case-definition criteria (active
rhabdomyolysis or creatine phosphokinase > four times the upper limit of normal), and
corresponding GP practices were asked to invite patient participation. Consenting patients
were requested to provide either saliva or blood samples and to complete an ethnicity
questionnaire. Control subjects were recruited from the same GP practice (saliva) or a small
number of practices (blood). Samples were forwarded for DNA extraction.
RESULTS
Thirty-six months of recruitment yielded DNA samples from 149 statin-induced myopathy
cases and 587 tolerant controls. Data show that contacting patients through their GP is a
reliable method for obtaining samples without compromising anonymity. Saliva collection
directly from patients was considerably less effective than blood sampling. After 10 months
of recruitment, saliva sampling was suspended in favour of blood sampling.
CONCLUSIONS
We demonstrate the potential of EHRs for identifying accurately phenotyped cases and
controls for pharmacogenetic studies. Recruitment was successful only because of the
willingness of GP practices to participate and the existence of strong doctor–patient
relationships. The present study provides a model that can be implemented in future
genetic analyses using EHRs.
WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Electronic health records, such as the Clinical Practice
Research Datalink (CPRD), are a potentially a valuable
resource for identifying rare events, such as rare
adverse drug reactions.
• To date, no study has used the CPRD to identify and
recruit patients to obtain biological samples for the
purpose of genetic studies.
• Current UK research governance procedures require
research and development approval from each
participating subject even in studies that are largely
non-interventional.
WHAT THIS STUDY ADDS
• This study demonstrates the utility of electronic
medical records in identifying well-phenotyped
patients with a rare adverse drug reaction
(statin-induced myopathy).
• A novel methodology is presented for the recruitment
of patients identified in the CPRD to a case–control
study.
• The present study highlights the need for streamlining
UK research governance procedures in order to
facilitate and expedite national studies using patients
recruited from multiple sites.
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Introduction
Healthcare systems are increasingly using computers to
record and store clinical information. Electronic health
records are also valuable for undertaking epidemiological
research using anonymized individual patient data. A
typical example is the General Practice Research Database,
recently renamed as the Clinical Practice Research Datalink
(CPRD). The CPRD has evolved over time, with increasing
population coverage and, through linkages with second-
ary care data and laboratory data, provides access to more
complete data sets. This makes it a highly valuable
resource that is widely used by academic, regulatory and
industry sectors. Although the CPRD has been widely used
for observational research, the data have not been linked
to biological samples, such as DNA. The UK biobank, in
contrast, currently has access to biological samples and
will eventually have access to linked health records. The
CPRD is much larger than the UK biobank and would be
particularly valuable to improve our understanding of the
genetic basis of rarer phenotypes, if these could be linked
to biological samples. One area of medical research that
would greatly benefit from this is the pharmacogenetics of
adverse drug reactions.
In pharmacogenetic studies, genetic markers (from
either candidate genes or the whole genome) from
patients who have experienced an adverse drug reaction
(cases) can be compared with those from patients who
have had no reaction (controls). In order to test the utility of
the CPRD for the recruitment of biological samples from
patients with adverse drug reactions, we have used statin-
induced myopathy as a paradigm. Although highly
successful in the reduction of low-density lipoprotein cho-
lesterol and the prevention of coronary heart disease [1–9],
statins are also associated with muscle toxicity. Manifesta-
tions including pain, raised creatine phosphokinase (CPK)
and, rarely, rhabdomyolysis [5, 10] are observed with all
types of statins and are more prevalent with higher doses.
Although the overall frequency of myopathy was found to
be low in clinical trials (<5%) [9], the incidence in clinical
practice is thought to be much higher (10–15%) [11, 12],
particularly the incidence of muscle pain without any rise in
CPK. A genome-wide association study revealed an asso-
ciation with an SLCO1B1 variant [13, 14]. Such pioneering
use of the CPRD would provide a golden opportunity to
identify large numbers of affected patients with other
adverse drug reactions in the future in order to elucidate
the genetic predisposing factors.
Methods
Ethical approval and research and
development approval
Ethical approval was obtained from the National Research
Ethics Committee North West 2 – Liverpool Central, and
approval to use the CPRD data was obtained from
the Independent Scientific Advisory Committee at the
Medicines and Healthcare products Regulatory Agency.
Research and development approval was obtained from
the host National Health Service (NHS) organization (Royal
Liverpool and Broadgreen University Hospitals Trust, Liv-
erpool, UK). In addition, because recruitment was to
involve general practitioner (GP) practices from across the
UK, it was necessary to obtain local research and develop-
ment approval from the primary care trusts (PCTs) of prac-
tices containing potentially eligible patients. For simplicity,
the principal investigator (PI) was also nominated as the
local collaborator (LC) for each site. The GP practices from
within a PCT were not contacted until site approval was
obtained from the medical board. Finally, all participants
provided informed consent in accordance with the Decla-
ration of Helsinki. A recruitment target of 250 cases and
500 controls was set.
Identification of patients through the Clinical
Practice Research Datalink
Cases and controls were considered only if they were at
least 18 years old and had been prescribed a statin, with
the first prescription at least 1 year after the start of CPRD
data collection. The first laboratory record of CPK measure-
ment or the first medical record in the electronic health
records of rhabdomyolysis in the 3 months following a
statin prescription and after 1 January 2000 was identified.
As such, all cases were considered to be current users
of statins at the date of the CPK measurement or
rhabdomyolysis. The index date was the date of the CPK
measurement or rhabdomyolysis record. The CPK values
were classified according to the upper limit of normal
(ULN; defined as 195 units l−1 for men and 170 units l−1 for
women). Cases with myocardial infarction, trauma or falls
recorded in the period from 1 month before to 2 weeks
after the CPK measurement or rhabdomyolysis were
excluded.
Phenotype definitions
Cases: phase I (months 1–10) Patients with a history of
rhabdomyolysis (high CPK levels associated with symp-
toms and evidence of myoglobin in the urine and often
accompanied by renal failure) or a rise in CPK of >10 times.
Cases: phase II (months 11–36) The criteria was relaxed
to include patients with a CPK > four times the ULN. Saliva
sample collection was halted.
Controls The selection criteria for controls were current
statin users (at least 90 days from the start of recruitment)
without a history of above-normal CPK values and no
history of recorded symptoms of myopathy. For saliva,
controls were also recruited from the same practice as
their cases during phase I.
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The following characteristics were measured at the
date of CPK measurement or rhabdomyolysis: age, gender,
body mass index, smoking status, number of prescriptions
issued in the 3 months before, prescribing in the 6 months
before of antihypertensives, drugs interacting with statins
through cytochrome P450 3A4 (CYP3A4) (amiodarone,
fibrates, cyclosporine, azole antifungals, macrolide antibi-
otics, protease inhibitors and calcium channel blockers),
drugs interacting through mechanisms other than a
CYP3A4 interacation (such as digoxin, warfarin, feno-
fibrate, gemfibrozil and nicotinic acid), oral corticosteroids,
medical history of diabetes mellitus, hypothyroidism,
hyperthyroidism, chronic obstructive pulmonary disease
and records in the 1 month before of myalgia.
Practice recruitment
The CPRD contacted GP practices by letter inviting them to
participate in the study. If willing, they were then asked to
review a list of eligible registered patients and remove any
they considered unsuitable for the study (due to, for
example, non-Caucasian descent). During phase I, the par-
ticipating practices were randomized to collection of
either blood or saliva case samples. During phase II, solely
blood samples were requested.
Patient recruitment
For recruitment of cases, GP practices were contacted by
letter and informed of potential cases for the study identi-
fied through the CPRD database. All samples were
anonymized by the GP using a unique CPRD identifier
code such that no patient identifiable information was
included with the sample or questionnaire. Each patient
letter contained an invitation letter signed by the GP, a
patient information leaflet with contact details of the
research team and a consent form, as well as a personal-
ized letterhead from the GP practice. Patients wishing to
participate were asked to sign the consent form and return
it to the practice, who forwarded it back to the CPRD.
Those practices asked to collect blood samples made
arrangements for patients to attend the practice, whilst
practices asked to collect saliva samples sent a supplied
saliva collection kit (Oragene DNA collection kit; DNA
Genotek, Ontario, Canada) to the patient’s home address.
All patients were also asked to complete an ethnicity ques-
tionnaire, which was sent along with their sample by mail
in a pre-addressed envelope to The University of Liverpool.
For the collection of control blood samples, control
subjects were selected from a small number of participat-
ing practices, whereas for the collection of saliva, control
subjects were selected from the same practice as their
matched cases.
Extraction of DNA
Genomic DNA was extracted from both whole blood and
saliva using standard automated procedures (Perkin Elmer
Chemagen, Baesweiler, Germany) and from saliva using
the standard protocol supplied by Genotek. The DNA con-
centration was measured using the Nanodrop ND-1000
Spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE, USA). For samples obtained through the CPRD, a
record of the DNA extraction date was logged onto the
Citrix server so that the GPs could be reimbursed for their
services.
Results
Research approvals
Individual applications for site approval were sent to 132
PCTs across England, Wales and Scotland. Although ethical
and Independent Scientific Advisory Committee approvals
were obtained within the required time frames, obtaining
local approval was a major challenge from 132 separate
sites (Figure 1) and took substantially longer, with the final
approval being granted more than 8 months after the
process began. The mean ± SD length of approval time
was 54.7 ± 40.6 days. Many PCTs raised queries, which
included questions about study design (despite the fact
that this had received peer-reviewed funding), the content
of the patient information leaflets (despite approval from
ethics committees), the need for approval from every GP
practice instead of the governing PCT (which would have
massively increased the bureaucratic burden) and the
need to have a local collaborator at every site (despite the
minimal nature of the intervention, i.e. a simple blood or
saliva collection with anonymization maintained).
Practice recruitment
During phase I, the CPRD received a positive response
from 51% of practices that were contacted to recruit blood
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Figure 1
Time taken to obtain local approval in England, Scotland and Wales
beginning with submission to National Institute for Health Research
(NIHR) Coordinated System for gaining NHS Permission (CSP) through the
integrated research application system (IRAS) to receipt of final site
approval. Each bar represents time to approval for an individual primary
care trust, with the mean time to approval indicated by the dashed line
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case samples and 57% for saliva samples (Table 1). There
were a number of reasons for practice non-involvement in
the study, including the following: nonresponse; simply
declining to participate; willing participation but no suit-
able patients; and refusal of permission to participate from
the primary care trust. From the list of potential myopathy
patients provided to practices by the CPRD, 43% were
deemed suitable by their GP in phase I (blood and saliva)
and 35% in phase II (Table 1). Ultimately, patient samples
were received from only 62 of 132 (47%) of the PCTs for
which research approval was obtained.
From a total of 953 patients identified within the CPRD
who fulfilled the criteria for statin myopathy, we were
able to obtain adequate DNA samples from 149 (Figure 2),
representing a recruitment rate of 15.6%. Of the 241
cases with severe myopathy (CPK > 10 times the ULN/
rhabdomyolysis), we were able to obtain adequate
samples from 32 (13.3%).
Patient recruitment and biological
sample receipt
During the period from June 2010 and April 2013, a total
of 754 patients, with accompanying biological sample
received, were recruited (Table 1). Of the 754 samples
received into the laboratory by post, 18 were excluded for
either sample identification reasons (mislabelling of blood
tubes; n = 10) or sample quality issues [low volume of
sample (n = 3) or poor DNA yield/quality (n = 1)]. A further
four case samples were excluded because closer inspec-
tion of phenotype identified them as not fulfilling inclu-
sion criteria. One hundred and thirteen cases were
excluded due to data extraction quality control issues,
which categorized individuals with an empty data field
CPK value as cases. These individuals, however, fulfilled the
criteria for controls and were subsequently reclassified.
Thus, in all, 736 individuals satisfied the sample and phe-
notype criteria of cases (n = 149) or controls (n = 587).
Recruitment progress over the 36 month period is
shown in Figure 3. Comprehensive phenotype data were
obtained for all included patients. A summary of clinical
and demographic variables of the cohort are listed in
Table 2. We have also been able to replicate the associa-
tion between statin-induced myopathy and the SLCO1B1
genetic polymorphism [15] previously described by Link
et al. [13], providing proof of concept for our approach to
case identification.
Discussion
This study has demonstrated that the CPRD can be used
for the identification and recruitment of patients where
there is a need to donate a biological sample. However,
there is a huge governance burden that represents a major
challenge.
A strength of the study was to use a rare adverse drug
reaction, statin-induced myopathy, as the paradigm; this
enabled the recruitment of 149 cases of statin-induced
myopathy and 587 drug-exposed controls. However, the
use of CPK elevation as an inclusion criterion led to initial
misclassification of 113 individuals (where a blank data
field was incorrectly taken to indicate an elevation) for
whom biological samples were received between months
5 and 29. A second line of quality control at the data extrac-
tion stage would have prevented this, and was imple-
mented for the remaining recruitment period. It was,
however, possible to re-assign these patients as controls.
We did not achieve our target of 250 cases, probably due
Table 1
Recruitment data for practices and patients recruited by the Clinical Practice Research Datalink using both blood and saliva sampling methods
Phase I‡ Phase II
Cases, blood Cases, saliva Controls, saliva Cases, blood Controls, blood
Practices
Invited to participate 109 101 13* 336 54
Declined to participate 15 14 0 19 1
Did not respond 23 17 1 142 37
Refused permission to participate 1 0 0 21 0
Current patients unsuitable 16 21 1 27 0
Recruited (%) 55 (51) 58 (57) 11 (85) 127 (38) 16 (30)
Patients
Potential 241§ 241§ 101† 953§ 3764
Suitable 102 121 77 505 1389
Declined (%) 14 (14) 46 (38) 0 (0) 123 (24) 1 (<1)
Awaiting patient response or inadequate sample (%) 44 (43) 53 (38) 39 (57) 298 (59) 839 (60)
Adequate sample received (%) 43 (42) 22 (24) 38 (43) 84 (17) 549 (30)
*Practices had previously obtained case saliva samples. †Patients were age and gender matched to saliva cases. ‡Phase I data include all saliva samples regardless of date of receipt
and case blood samples received up to 31 March 2011. §Total includes all patients on the Clinical Practice Research Datalink fulfilling myopathy criteria (creatine phosphokinase >
10 times the upper limit of normal for phase I and > four times the upper limit of normal for phase II) from recruited and nonrecruited practices.
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to several reasons, including the governance burden, the
difficulties in identifying the right patients in the database,
the fact that we concentrated only on elevations in CPK
levels, and the lack of willingness of all practices (53%) to
take part in the research.
A total of only 14 of 754 samples (1.8%) received were
excluded for reasons directly related to the general prac-
tice physician or patient’s handling of the samples (either
mislabelled tube (n = 10) or poor sample quality (n = 4).
Handwritten transcribing of complex alphanumeric
Patients in CPRD
prescribed a statin
(n = 641,703)
CPK measurement
available
(n = 127,209)
No CPK Measurement
available
(n = 514,494)
Normal CPK (<4xULN)
(n = 126,315)
CPK>4xULN
(n = 712)
Adequate DNA
Sample Obtained
(n = 115)
Adequate DNA
Sample Obtained
(n = 34)
Unable to
recruit/inadequate
sample received
(n = 597)
Unable to
recruit/inadequate
sample received
(n = 207)
CPK>10xULN/
Rhabdomyolysis
(n = 241)
Figure 2
Schematic diagram showing the total number of potential statin-induced myopathy patients within the Clinical Practice Research Datalink (CPRD) and the
numbers fulfilling the inclusion criteria who were ultimately recruited into the study
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Figure 3
Cumulative recruitment of statin-induced myopathy cases and controls (n = 736) over the 36 month period of study recruitment. Data are based on the date
on which a valid biological sample was received by the laboratory and include only viable patients. , cases;■, controls
Patient recruitment using electronic health records
Br J Clin Pharmacol / 77:5 / 835
patient codes by the physician accounted for the majority
of issues. This was addressed later in the study by provid-
ing printed labels.
Only 1 of 60 (1.6%) saliva samples provided directly by
patients without physician contact was omitted due to
poor DNA yield, suggesting that patients were capable of
providing sufficient sample without clinical supervision.
However, the lack of the reassurance of providing a bio-
logical sample directly to a clinician is likely to be a key
reason for the decline rate for saliva samples (38%) com-
pared with blood samples (14%) in recruitment phase I.
Given the higher ‘success rate’ of blood sample recruit-
ment, we concentrated only on recruitment via blood
donation.
The lack of a central, nationalized healthcare research
and development approval system meant that 132 indi-
vidual local primary care provider approval applications
had to be processed. This caused significant delays to the
study recruitment phase, given that the mean time from
application to approval was 54.7 days and the longest time
for a single approval was 218 days. The governance
burden placed on researchers in the UK has been high-
lighted by other studies [16, 17]. This led to the review of
research governance by the Academy of Medical Sciences
[18], and has led to the setting up of the Health Research
Authority in the UK. A single, streamlined approval process
would considerably reduce the administrative burden and
lead time for performing studies using electronic health
records in multiple sites, but whether this can be achieved
is unclear.
Using the recruitment methodology outlined, we were
able to recruit a significant number of cases of stain-
induced myopathy (n = 149). However, this figure repre-
sents merely 15.6% of the potential cases available.
Table 2
Summary of clinical and demographic data from cases and controls from whom a viable DNA sample was obtained
Variable Missing data (n) Controls (n = 587) Cases (n = 149)
Statin at index
Simvastatin 344 (59%) 98 (66%)
Atorvastatin 175 (29%) 34 (23%)
Rosuvastatin 29 (5%) 9 (6%)
Fluvastatin 11 (2%) 2 (1%)
Pravastatin 26 (4%) 6 (4%)
Ceruvastatin 2 (<1%) 0 (0%)
Mean daily dose [mg day−1 (SD)] 30.9 (+15.9) 31.2 (+19.0)
Mean age [years (SD)]* 69.7 (9.3) 66.2 (10.6)
Gender 64% male, 36% female 72% male, 28% female
Mean body mass index* 66 (9%) 28.8 (+5.4) 29.5 (+5.0)
Smoking status 36 (5%)
Nonsmoker 237 (42%) 61 (43%)
Ex-smoker 238 (43%) 64 (45%)
Smoker 83 (15%) 17 (12%)
Comedications in 6 months prior to index
Antihypertensives 479 (82%) 108 (73%)
CYP3A4 inhibitors* 72 (12%) 20 (13%)
Known statin interactor (non-CYP3A4 substrate)† 51 (9%) 11 (7%)
Oral corticosteroids 23 (4%) 4 (3%)
Occurrence in previous 6 months or 2 weeks after index
Cramps 5 (1%) 3 (2%)
Myocardial infarction 5 (1%) 1 (<1%)
Renal failure 16 (3%) 5
Trauma 1 (<1%) 1 (<1%)
Falls 2 (<1%) 0 (0%)
Previous history (any time prior to index)
Type 2 diabetes 154 (26%) 45 (30%)
Alcohol dependence 26 (4%) 6 (4%)
Asthma 75 (13%) 20 (13%)
Atrial fibrillation 61 (10%) 13 (9%)
Chronic obstructive pulmonary disease 41 (7%) 7 (5%)
Hypertension 382 (65%) 73 (49%)
Hyperthyroidism 10 (2%) 3 (2%)
Hypothyroidism 47 (8%) 14 (9%)
*CYP3A4-interacting comedications were amiodarone, cyclosporine, azole antifungals, macrolide antibiotics, protease inhibitors and calcium channel blockers. †Non-CYP3A4-
interacting comedications recorded were fenofibrate, gemfibrozil, digoxin, warfarin and nicotinic acid.
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Although many of the remaining cases may have proved
to be unsuitable, it is possible that, with streamlined gov-
ernance procedures, many of these ‘missed opportunities’
could have been taken and the recruitment targets met.
Conclusions
The importance of electronic health record databases for
conducting research has been widely acknowledged; to
date, they have mainly been used for epidemiological
research. A case in point is the CPRD, which has resulted
in 1083 peer-reviewed publications (as of June 2013).
However, such population databases may also serve as a
time- and cost-efficient method for identifying patients
with rare disorders, including those caused by adverse
drug reactions. Our study using statin myopathy as a para-
digm of a rare adverse event clearly shows that CPRD can
also be configured to obtain significant numbers of viable
biological samples for the purpose of pharmacogenomics
studies. Given that rare adverse drug reactions have a sig-
nificant genetic predisposition [19], the use of CPRD and
other databases has the potential to revolutionize research
in this field.
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